S,S-diphenyl-N-[4-(2-ethyl-4-m-tolyl-thiazol-5-yl)-pyridin-2-yl]-sulfoximine | 943761-88-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: S,S-diphenyl-N-[4-(2-ethyl-4-m-tolyl-thiazol-5-yl)-pyridin-2-yl]-sulfoximine
• 英文别名: S,S-diphenyl-N-[4-(2-ethyl-4-m-tolyl-1,3-thiazol-5-yl)-pyridin-2-yl]-sulfoximine；[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]pyridin-2-yl]imino-oxo-diphenyl-lambda6-sulfane；[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]pyridin-2-yl]imino-oxo-diphenyl-λ6-sulfane
• CAS: 943761-88-4
• 化学式: C₂₉H₂₅N₃OS₂
• 分子量: 495.669
• InChiKey: URQAAVISVMYJOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  91.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Sulfoximine Derivatives as p38 MAP Kinase Inhibitors
  申请人：Shetty Shanker Jayram

  公开号：US20100240709A1

  公开（公告）日：2010-09-23

  The present invention relates to novel compounds of general formula (I), their regioisomers, tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (I), their regioisomers, their tautomeric forms, their pharmaceutically acceptable salts pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

  本发明涉及一般式（I）的新化合物及其区位异构体、互变异构体、其合成中所涉及的新中间体、其药学上可接受的盐和含有它们的药物组合物。本发明还涉及制备一般式（I）的化合物、它们的区位异构体、它们的互变异构体、其药学上可接受的盐、含有它们的药物组合物以及其合成中所涉及的新中间体的方法。
• SULFOXIMINE DERIVATIVES AS p38 MAP KINASE INHIBITORS
  申请人：CADILA HEALTHCARE LIMITED

  公开号：EP1971603B1

  公开（公告）日：2012-03-14
• [EN] SULFOXIMINE DERIVATIVES AS p38 MAP KINASE INHIBITORS<br/>[FR] DERIVES DE LA SULFOXIMINE UTILISES COMME INHIBITEURS DE LA P38 MAP KINASE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2007077574A2

  公开（公告）日：2007-07-12

  (EN) The present invention relates to novel compounds of general formula (I), their regioisorriers, tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (I), their regioisomers, their tautomeric forms, their pharmaceutically acceptable salts pharmaceutical compositions containing them, and novel intermediates involved iil their synthesis.(FR) L'invention se rapporte à de nouveaux composés de la formule générale (I), à leurs régioisomères, à leurs formes tautomères et à de nouveaux intermédiaires intervenant dans leur synthèse, à leurs sels pharmaceutiquement acceptables et à des compositions pharmaceutiques les contenant. L'invention concerne également un procédé de préparation de composés de la formule générale (I), de leurs régioisomères, de leurs formes tautomères, de leurs sels pharmaceutiquement acceptables, de compositions pharmaceutiques les contenant et de nouveaux intermédiaires intervenant dans leur synthèse.